eGenesis

CRISPR for xenotransplantation

eGenesis is using gene editing to meet patient demand for organ transplants. Every day, 20 patients die before receiving a needed transplant. Xenotransplantation, the implantation of organs from non-human animal sources, could solve this demand but comes with its own problems of infection and rejection. eGenesis aims to make xenotransplantation safe and effective by creating an unlimited supply of HuCo organs and cells. This involves gene editing to inactivate infectious sequences in the porcine genome and to modify foreign sites to prevent immune detection. eGenesis achieves this with their Genome Engineering and Production platform with several programs in development for kidney, heart and liver organs.